Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Inhibition of heregulin expression blocks tumorigenicity and metastasis of breast cancer

Journal Article · · Oncogene
OSTI ID:837231
The growth factor Heregulin (HRG) is expressed in 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells. Our investigation into whether blockage of HRG reduces the aggressiveness of breast cancer cells demonstrated that transfection of MDA-MB-231 with an HRG antisense cDNA suppressed proliferation, tumorigenicity, and metastasis. Blockage of the aggressive phenotype is mediated possibly through inactivation of the erbB signaling pathways and a decrease in MMP-9 activity. Our study is the first to report that HRG is a key promoter of breast cancer progression and should be deemed as a potential target in developing therapies for the treatment of breast carcinomas.
Research Organization:
Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA (US)
Sponsoring Organization:
National Institutes of Health (US)
DOE Contract Number:
AC03-76SF00098
OSTI ID:
837231
Report Number(s):
LBNL--49351
Journal Information:
Oncogene, Journal Name: Oncogene Vol. 22
Country of Publication:
United States
Language:
English

Similar Records

Heregulin regulates the actin cytoskeleton and promotes invasiveproperties in breast cancer cell lines
Journal Article · Fri Oct 01 00:00:00 EDT 1999 · Cancer Research · OSTI ID:894537

Heregulin, a new regulator of telomere length in human cells
Journal Article · Tue Jul 21 20:00:00 EDT 2015 · Oncotarget · OSTI ID:1627987

Action of hexachlorobenzene on tumor growth and metastasis in different experimental models
Journal Article · Wed May 01 00:00:00 EDT 2013 · Toxicology and Applied Pharmacology · OSTI ID:22285287